Pulling SEC filings + quote and writing the call…

COMPUGEN LTD
Next earnings Aug 4, 2026 · consensus $-0.08 EPS, $1.64M rev
Revenue grew 161.1% YoY.
Revenue (FY2025) $72.8M · FY2025
Quality fundamentals and an attractive price line up (~533% below fair value) — the rarer case where both the business and the entry look good.
COMPUGEN LTD shows $72.8M in FY2025 revenue (+161.1% YoY), a 48.6% net margin, and 34.4% ROE.
Supporting the case: revenue grew 161.1% YoY; strong net margin (48.6%); high return on equity (34.4%); undemanding valuation (P/E 6.0).
Is CGEN a buy? The one-page verdict, explained →
High-conviction BUY: a wider spread keeps more of the upside while the short call still cuts cost and decay.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $6.00M | $7.50M | $33.5M | $27.9M | $72.8M |
| Gross profit | $5.32M | $6.53M | $31.5M | $19.9M | $63.5M |
| Operating income | -$35.1M | -$35.4M | -$13.0M | -$14.9M | $31.3M |
| Net income | -$34.2M | -$33.7M | -$18.8M | -$14.2M | $35.3M |
| Diluted EPS | -$0.41 | -$0.39 | -$0.21 | -$0.16 | $0.38 |
| Net margin | -570.0% | -449.3% | -56.1% | -51.1% | 48.6% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Sources: SEC EDGAR (CIK 0001119774, latest EFFECT filed 2026-06-08) · EODHD · as of 7/4/2026, 10:40:05 PM.
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 4, 2026, 6:40 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
Last 90 days: 0 open-market buys · 7 sales
| 2026-04-24 | Levine Zurit SVP, Business Development | Exercise | 2.00K @ $1.15 | $2.30K |
| 2026-04-24 | Levine Zurit SVP, Business Development | Sell | 2.00K @ $3.20 | $6.40K |
| 2026-04-24 | Ophir Eran President and CEO | Exercise | 5.00K @ $0.83 | $4.15K |
| 2026-04-24 | Ophir Eran President and CEO | Sell | 5.00K @ $3.20 | $16.0K |
| 2026-04-14 | Ophir Eran President and CEO | Exercise | 5.00K @ $0.83 | $4.15K |
| 2026-04-14 | Ophir Eran President and CEO | Sell | 5.00K @ $2.90 | $14.5K |
| 2026-04-14 | Levine Zurit SVP, Business Development | Exercise | 2.00K @ $1.15 | $2.30K |
| 2026-04-14 | Levine Zurit SVP, Business Development | Sell | 2.00K @ $2.80 | $5.60K |
| 2026-04-10 | Levine Zurit SVP, Business Development | Exercise | 1.13K @ $0.83 | $932.85 |
| 2026-04-10 | Levine Zurit SVP, Business Development | Exercise | 2.00K @ $1.15 | $2.30K |
| 2026-04-10 | Levine Zurit SVP, Business Development | Sell | 3.13K @ $2.56 | $8.01K |
| 2026-04-08 | Levine Zurit SVP, Business Development | Exercise | 4.38K @ $0.83 | $3.63K |
| ARK Investment Management | 1.05M sh | $2.24M |
As of each fund’s latest quarterly 13F — a delayed snapshot, not a live position. All tracked funds →
1195 tracked peers · median